{"altmetric_id":6079975,"counts":{"readers":{"mendeley":19,"citeulike":0,"connotea":0},"total":{"posts_count":6},"twitter":{"unique_users_count":3,"unique_users":["mtmdphd","ph_ahmd1","Aurora_Cancer"],"posts_count":6}},"selected_quotes":["Final Report Ph2 Imatinib + Hyper-CVAD For 1L Ph+ Adult ALL"],"citation":{"altmetric_jid":"4f6fa61a3cf058f6100075cb","authors":["Daver N","Thomas D","Ravandi F","Cortes J","Garris R","Jabbour E","Garcia-Manero G","Borthakur G","Kadia T","Rytting M","Konopleva M","Kantarjian H","O' Brien S","Naval Daver","Deborah Thomas","Farhad Ravandi","Jorge Cortes","Rebecca Garris","Elias Jabbour","Guillermo Garcia-Manero","Gautam Borthakur","Tapan Kadia","Michael Rytting","Marina Konopleva","Hagop Kantarjian","Susan O\u2019Brien","N. Daver","D. Thomas","F. Ravandi","J. Cortes","R. Garris","E. Jabbour","G. Garcia-Manero","G. Borthakur","T. Kadia","M. Rytting","M. Konopleva","H. Kantarjian","S. O'Brien"],"doi":"10.3324\/haematol.2014.118588","endpage":"661","first_seen_on":"2016-03-04T20:49:15+00:00","funders":["nci"],"issns":["0390-6078","1592-8721"],"issue":"5","journal":"Haematologica","last_mentioned_on":1472740075,"links":["http:\/\/www.haematologica.org\/content\/100\/5\/653"],"pdf_url":"http:\/\/www.haematologica.org\/content\/haematol\/100\/5\/653.full.pdf","pmid":"25682595","pubdate":"2015-02-14T00:00:00+00:00","publisher":"Haematologica","publisher_subjects":[{"name":"Cardiovascular Medicine And Haematology","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"653","subjects":["hematology"],"title":"Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia.","type":"article","uri":"http:\/\/www.haematologica.org\/cgi\/doi\/10.3324\/haematol.2014.118588","volume":"100","mendeley_url":"http:\/\/www.mendeley.com\/research\/final-report-phase-ii-study-imatinib-mesylate-hypercvad-frontline-treatment-adult-patients-philadelp"},"altmetric_score":{"score":1.6,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":1.6},"context_for_score":{"all":{"total_number_of_other_articles":8314034,"mean":7.0059620328577,"rank":3903305,"this_scored_higher_than_pct":52,"this_scored_higher_than":4377322,"rank_type":"exact","sample_size":8314034,"percentile":52},"similar_age_3m":{"total_number_of_other_articles":288095,"mean":11.041193374384,"rank":130584,"this_scored_higher_than_pct":54,"this_scored_higher_than":155713,"rank_type":"exact","sample_size":288095,"percentile":54},"this_journal":{"total_number_of_other_articles":1190,"mean":5.3448948696384,"rank":568,"this_scored_higher_than_pct":51,"this_scored_higher_than":616,"rank_type":"exact","sample_size":1190,"percentile":51},"similar_age_this_journal_3m":{"total_number_of_other_articles":58,"mean":1.7982456140351,"rank":19,"this_scored_higher_than_pct":67,"this_scored_higher_than":39,"rank_type":"exact","sample_size":58,"percentile":67}}},"demographics":{"poster_types":{"member_of_the_public":2,"researcher":1},"users":{"twitter":{"cohorts":{"Scientists":1,"Members of the public":2}},"mendeley":{"by_status":{"Unspecified":1,"Professor > Associate Professor":4,"Researcher":2,"Student  > Doctoral Student":2,"Student  > Ph. D. Student":2,"Student  > Postgraduate":4,"Other":1,"Student  > Bachelor":1,"Professor":2},"by_discipline":{"Medicine and Dentistry":14,"Physics and Astronomy":1,"Agricultural and Biological Sciences":2,"Unspecified":2}}},"geo":{"twitter":{"US":2,"SA":1},"mendeley":{"US":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/757601361559191553","license":"gnip","citation_ids":[6079975],"posted_on":"2016-07-25T15:40:14+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15360},"tweet_id":"757601361559191553"},{"url":"http:\/\/twitter.com\/ph_ahmd1\/statuses\/757602359769989120","license":"gnip","rt":["mtmdphd"],"citation_ids":[6079975],"posted_on":"2016-07-25T15:44:12+00:00","author":{"name":"Ahmed Alamri","image":"https:\/\/pbs.twimg.com\/profile_images\/771522818504794112\/A3_oftAZ_normal.jpg","description":"Pharmacist , working at @Roche Oncology","id_on_source":"ph_ahmd1","tweeter_id":"2263561521","geo":{"lt":21.51694,"ln":39.21917,"country":"SA"},"followers":318},"tweet_id":"757602359769989120"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/760886863406174209","license":"gnip","citation_ids":[6079975],"posted_on":"2016-08-03T17:15:39+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15360},"tweet_id":"760886863406174209"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/761545411127541760","license":"gnip","citation_ids":[6079975],"posted_on":"2016-08-05T12:52:29+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15360},"tweet_id":"761545411127541760"},{"url":"http:\/\/twitter.com\/Aurora_Cancer\/statuses\/761551332125863936","license":"gnip","rt":["mtmdphd"],"citation_ids":[6079975],"posted_on":"2016-08-05T13:16:01+00:00","author":{"name":"Aurora Cancer Care","url":"https:\/\/www.aurorahealthcare.org\/services\/cancer","image":"https:\/\/pbs.twimg.com\/profile_images\/510102625086210048\/qnjNLC3v_normal.jpeg","description":"Aurora Cancer Care - part of @Aurora_Health","id_on_source":"Aurora_Cancer","tweeter_id":"2727758072","geo":{"lt":40.00032,"ln":-89.25037,"country":"US"},"followers":438},"tweet_id":"761551332125863936"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/771353898292502528","license":"gnip","citation_ids":[6079975],"posted_on":"2016-09-01T14:27:55+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15360},"tweet_id":"771353898292502528"}]}}